InnoCare Pharma (9969) Q3 2024 earnings summary

Executive summary

• Achieved 76.3% year-over-year drug sales growth in Q3 2024 and 45.2% growth for Q1–Q3 2024, driven by orelabrutinib performance.

• Orelabrutinib sales reached RMB693 million in Q1–Q3 2024, with Q3 sales up 75.5% year-over-year.

• Gross profit margin improved to 86.0% for the first three quarters of 2024, up from 81.2% year-over-year.

• Total loss for Q1–Q3 2024 narrowed by 47.1% to RMB285 million, attributed to sales growth, cost efficiency, and FX gains.

• Cash and related balances stood at RMB7.8 billion as of September 30, 2024, supporting ongoing R&D and commercialization.

Financial highlights

• Q3 2024 drug sales: RMB479 million (+76.3% yoy); Q1–Q3 2024 drug sales: RMB695 million (+45.2% yoy).

• Q3 2024 operating revenue: RMB278 million, up 74% year-over-year.

• R&D expenses for Q1–Q3 2024: RMB615 million, up 11.9% year-over-year.

• Basic and diluted EPS for Q1–Q3 2024: -0.16 RMB/share.

• Net cash outflow from operating activities for Q1–Q3 2024: RMB333 million.

Outlook and guidance

• Full-year orelabrutinib sales growth guidance raised to over 45% due to strong performance.

• Remaining IPO and subscription proceeds will be fully utilized by 2026–2027, mainly for clinical trials, product launches, and R&D.

• MZL indication and expanded NRDL coverage expected to drive future sales growth.

• No specific breakeven timetable provided; focus remains on R&D investment and commercialization expansion.

• Multiple late-stage clinical trials and regulatory submissions planned for 2025.